TRIM47 Promotes Atherosclerosis by Activating NF‐κB Signaling via IκBα Ubiquitination
Drug Development Research · 2026
DOI: 10.1002/ddr.70264 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Development Research, 2026. Verfasst von Xiaoming Qin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Shanghai Jiaotong University School of Medicine Xinhua Hospital, Shanghai, China. Hauptthemen laut MEDLINE: Atherosclerosis, NF-kappa B, NF-KappaB Inhibitor alpha, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Atherosclerosis, a major contributor to cardiovascular diseases, is characterized by chronic inflammation in arterial walls. The role of NF‐κB signaling in this process is well‐established, but the upstream regulators remain incompletely understood. This study explored the role of TRIM47, an E3 ubiquitin ligase, in promoting atherosclerosis through NF‐κB activation. In vitro studies used human umbilical vein endothelial cells (EC) treated with oxidized low‐density lipoprotein (ox‐LDL). TRIM47 expression was modulated using siRNA knockdown and overexpression plasmids. Inflammation markers, cell viability, and NF‐κB activation were assessed. In vivo studies utilized ApoE‐/‐ mice fed a high‐fat diet and treated with adenovirus‐mediated TRIM47 knockdown. ox‐LDL treatment increased TRIM47 expression in EC, alongside elevated inflammatory markers, and reduced cell viability. TRIM47 overexpression exacerbated ox‐LDL‐induced inflammation, while knockdown attenuated these effects. Mechanistically, TRIM47 directly interacted with IκBα, promoting its ubiquitination and degradation, leading to enhanced NF‐κB activation. In ApoE‐/‐ mice, TRIM47 knockdown significantly reduced atherosclerotic plaque formation and lesion size. This study identified TRIM47 as a novel regulator of atherosclerosis progression through IκBα ubiquitination and NF‐κB activation. TRIM47 knockdown attenuated vascular inflammation and atherosclerotic plaque formation. The findings suggested that TRIM47 might be a potential therapeutic target for the treatment of atherosclerosis and related cardiovascular diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Shanghai Jiaotong University School of Medicine Xinhua Hospital, Shanghai, China.
- Department of Cardiology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China.
ORCID-Profile: Yidong Wei
Zitieren
APA
Qin, X., Luo, J., Yuan, Y., Liu, B., Zhang, X., Zhang, Y., Fang, Y., & Wei, Y. (2026). TRIM47 Promotes Atherosclerosis by Activating NF‐κB Signaling via IκBα Ubiquitination. Drug Development Research. https://doi.org/10.1002/ddr.70264
Vancouver
Qin X, Luo J, Yuan Y, Liu B, Zhang X, Zhang Y, et al. TRIM47 Promotes Atherosclerosis by Activating NF‐κB Signaling via IκBα Ubiquitination. Drug Development Research. 2026. doi:10.1002/ddr.70264
BibTeX
@article{Qin2026,
author = {Qin, Xiaoming and Luo, Jiachen and Yuan, Yiqian and Liu, Baoxin and Zhang, Xingxu and Zhang, Yiwei and Fang, Yuan and Wei, Yidong},
title = {TRIM47 Promotes Atherosclerosis by Activating NF‐κB Signaling via IκBα Ubiquitination},
journal = {Drug Development Research},
year = {2026},
doi = {10.1002/ddr.70264}
}
EUVIMED